Deleted Tweets From Scott Gottlieb, R-D.C.
Scott Gottlieb's accounts: SteveFDA
Tracked Between: October 20, 2017-January 20, 2021
SteveFDA (R-D.C.)
@SGottliebFDA
#FDA’s new approach to pediatric rare disease drug development could streamline clinical studies and reduce # of patients needed in placebo arms #GaucherDisease https://t.co/jHhlwEhmH8
SteveFDA (R-D.C.)
@SGottliebFDA
RT @US_FDA: Working w/ EMA, FDA has drafted an approach to pediatric rare disease drug dev that could eliminate need for certai… https://t.co/3GrOsuvunN
SteveFDA (R-D.C.)
@SGottliebFDA
RT @BioCentury: FDA issues guidance for rare pediatric disease drug development https://t.co/2ox4daXPFj
SteveFDA (R-D.C.)
@SGottliebFDA
RT @SGottliebFDA: #FDA’s new approach to pediatric rare disease drug development could streamline clinical studies and reduce # of pa… https://t.co/0WHAQamwXQ
SteveFDA (R-D.C.)
@SGottliebFDA
RT @SGottliebFDA: #FDA Launches Predictive Toxicology Roadmap to Enable Advances in Toxicity Testing that improve efficiency of Drug… https://t.co/OulsYbe8lW
SteveFDA (R-D.C.)
@SGottliebFDA
RT @tmprowell: Important for regulators to look up from review of individual drugs or trials and ask: Are we making progress in t… QT @FDAOncology: This dedication toward progress in a disease rather than looking at individual drug applications requires flexibili… https://t.co/QhU8gNThlm)
SteveFDA (R-D.C.)
@SGottliebFDA
Great, collaborative work is taking place in regions across country to support farmers and state regulators with implementation of the #FSMA Produce Safety Rule. Read more here: https://t.co/lJGuFJ8II4
SteveFDA (R-D.C.)
@SGottliebFDA
RT @SGottliebFDA: Great, collaborative work is taking place in regions across country to support farmers and state regulators with im… https://t.co/ACGx9NwBUa
SteveFDA (R-D.C.)
@SGottliebFDA
The Produce Safety Network establishes regionally based policy & regulatory experts throughout the country, making them uniquely suited to address the produce issues specific to states they’re supporting.
SteveFDA (R-D.C.)
@SGottliebFDA
RT @SenAlexander: Great to have @NIHDirector & @SGottliebFDA back in the HELP committee today to update us on their work to implement… https://t.co/dr7YmJiduK
SteveFDA (R-D.C.)
@SGottliebFDA
Post-approval studies enhance patient safety & public health, can lead to safety labeling changes, support expanded use of drug, alleviate risk concerns https://t.co/6thz5nJZij
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDAfood: FDA food defense experts discuss what the agency is doing to protect our food supply from intentional adulteration… https://t.co/EEYsqQ1Ary
SteveFDA (R-D.C.)
@SGottliebFDA
Today #FDA reports that drug post-marketing study backlogs are way down; more post-marketing requirements (PMRs) and post-marketing commitments (PMCs) are progressing to completion https://t.co/6thz5nJZij
SteveFDA (R-D.C.)
@SGottliebFDA
#FDA must encourage the development of tools that can help people be more informed about their health. We know our regulations play a crucial role in the innovation of #digitalhealth; 3 guidances released today provide greater clarity on our role https://
SteveFDA (R-D.C.)
@SGottliebFDA
#FDA’s new Predictive Toxicology Roadmap and novel methods for toxicity testing will help us move safe products to market more efficiently: https://t.co/wpxfI7qPg9
SteveFDA (R-D.C.)
@SGottliebFDA
My remarks today; as prepared for oral testimony before U.S. Senate HELP Committee on 21st Century Cures Act https://t.co/vqs4yy7uxJ @GOPHELP @HELPCmteDems
SteveFDA (R-D.C.)
@SGottliebFDA
RT @SGottliebFDA: Today #FDA reports that drug post-marketing study backlogs are way down; more post-marketing requirements (PMRs) an… https://t.co/TyOZkmQMKh
SteveFDA (R-D.C.)
@SGottliebFDA
RT @SGottliebFDA: My remarks today; as prepared for oral testimony before U.S. Senate HELP Committee on 21st Century Cures Act… https://t.co/K9yAtN80oh
SteveFDA (R-D.C.)
@SGottliebFDA
RT @SGottliebFDA: #FDA must encourage the development of tools that can help people be more informed about their health. We know our… https://t.co/hxrReiayUc
SteveFDA (R-D.C.)
@SGottliebFDA
RT @SGottliebFDA: #FDA public workshop begins today on Advancing Use of Patient Preference Information as Scientific Evidence in Medi… https://t.co/hWLuqltmU4